{
    "paper_id": "188e7ff1e260864c89f266b5597de26d69a84660",
    "metadata": {
        "title": "Clinical trials on drug repositioning for COVID-19 treatment",
        "authors": [
            {
                "first": "Sandro",
                "middle": [
                    "G"
                ],
                "last": "Viveiros",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Universidade Federal Fluminense",
                    "location": {
                        "settlement": "Rio de Janeiro",
                        "country": "Brazil"
                    }
                },
                "email": "sandrogvr@gmail.com"
            },
            {
                "first": "Rosa",
                "middle": [],
                "last": "",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Wilson",
                "middle": [
                    "C"
                ],
                "last": "Santos",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Universidade Federal Fluminense",
                    "location": {
                        "settlement": "Rio de Janeiro",
                        "country": "Brazil"
                    }
                },
                "email": ""
            }
        ]
    },
    "abstract": [
        {
            "text": "Rosa SGV and Santos WC. Clinical trials on drug repositioning for COVID-19 treatment. Rev Panam Salud Publica. 2020;44:e40. ABSTRACT The World Health Organization (WHO) was informed on December 2019 about a coronavirus pneumonia outbreak in Wuhan, Hubei province (China). Subsequently, on March 12, 2020, 125,048 cases and 4,614 deaths were reported. Coronavirus is an enveloped RNA virus, from the genus Betacoronavirus, that is distributed in birds, humans, and other mammals. WHO has named the novel coronavirus disease as COVID-19. More than 80 clinical trials have been launched to test coronavirus treatment, including some drug repurposing or repositioning for COVID-19. Hence, we performed a search in March 2020 of the clinicaltrials.gov database.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        },
        {
            "text": "The eligibility criteria for the retrieved studies were: contain a clinicaltrials.gov base identifier number; describe the number of participants and the period for the study; describe the participants' clinical conditions; and utilize interventions with medicines already studied or approved for any other disease in patients infected with the novel coronavirus SARS-CoV-2 (2019-nCoV). It is essential to emphasize that this article only captured trials listed in the clinicaltrials.gov database. We identified 24 clinical trials, involving more than 20 medicines, such as human immunoglobulin, interferons, chloroquine, hydroxychloroquine, arbidol, remdesivir, favipiravir, lopinavir, ritonavir, oseltamivir, methylprednisolone, bevacizumab, and traditional Chinese medicines (TCM).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        },
        {
            "text": "Although drug repurposing has some limitations, repositioning clinical trials may represent an attractive strategy because they facilitate the discovery of new classes of medicines; they have lower costs and take less time to reach the market; and there are existing pharmaceutical supply chains for formulation and distribution.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        }
    ],
    "body_text": [
        {
            "text": "The World Health Organization (WHO) was informed on December 31, 2019, about a pneumonia outbreak in Wuhan, Hubei province (China), a city with 11 million inhabitants. By March 12, 2020 , there were 125 048 cases and 4 614 deaths (nearly 3.7% of cases) reported for the novel coronavirus (1), named 2019-novel coronavirus (2019-nCoV), and later renamed as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (2). The WHO named this novel coronavirus disease as COVID-19 (1, 2) , and there have been confirmed cases in 117 countries or territories outside China, including Japan, the United States of America, Italy, Iran, and Brazil (1) . Coronavirus is an enveloped RNA virus, from the genus Betacoronavirus, that is distributed in birds, humans, and other mammals (3, 4) . New evidence indicates a link between SARS-CoV-2 and bat coronavirus (3) . Six species of coronavirus are known as infectious in humans, four of which (229E, OC43, NL63, and HKU1) cause common cold symptoms (4) . However, some authors have claimed that SARS-CoV-2 is even related to the coronavirus species responsible for the severe acute respiratory syndrome (SARS-CoV) as well as Middle East Respiratory Syndrome (MERS-CoV), which have zoonotic origins linked to severe significant illness with higher mortality (3, 4) . For example, in July 2003, the WHO reported 8 437 SARS-CoV cases, especially in China and Hong Kong, with 813 related deaths (5) . Concerning MERS-CoV, from June 2012 to April 2018, 2 206 people were infected in 27 countries, 1 831 cases in Saudi Arabia, with 787 deaths (6) . Unfortunately, there are no vaccines or medicines approved for the novel coronavirus infection (7) , but more than 80 clinical trials have been launched to test coronavirus treatments, including some drug repurposing or repositioning for COVID-19 (8) . Drug repositioning for other neglected diseases is an essential and universal strategy in the development of new drugs due to: a) lower costs and reduced time to reach the market because some clinical trial steps might not be required, especially concerning phases I and II; b) existing pharmaceutical supply chains are available for formulation and distribution; c) the possibility of combinations with other drugs in treatments that are more effective than monotherapy; and d) may facilitate the discovery of new mechanisms of action for old drugs and new classes of medicines (9, 10) .",
            "cite_spans": [
                {
                    "start": 171,
                    "end": 185,
                    "text": "March 12, 2020",
                    "ref_id": null
                },
                {
                    "start": 479,
                    "end": 482,
                    "text": "(1,",
                    "ref_id": "BIBREF0"
                },
                {
                    "start": 483,
                    "end": 485,
                    "text": "2)",
                    "ref_id": "BIBREF1"
                },
                {
                    "start": 642,
                    "end": 645,
                    "text": "(1)",
                    "ref_id": "BIBREF0"
                },
                {
                    "start": 775,
                    "end": 778,
                    "text": "(3,",
                    "ref_id": "BIBREF2"
                },
                {
                    "start": 779,
                    "end": 781,
                    "text": "4)",
                    "ref_id": "BIBREF3"
                },
                {
                    "start": 853,
                    "end": 856,
                    "text": "(3)",
                    "ref_id": "BIBREF2"
                },
                {
                    "start": 991,
                    "end": 994,
                    "text": "(4)",
                    "ref_id": "BIBREF3"
                },
                {
                    "start": 1299,
                    "end": 1302,
                    "text": "(3,",
                    "ref_id": "BIBREF2"
                },
                {
                    "start": 1303,
                    "end": 1305,
                    "text": "4)",
                    "ref_id": "BIBREF3"
                },
                {
                    "start": 1433,
                    "end": 1436,
                    "text": "(5)",
                    "ref_id": "BIBREF4"
                },
                {
                    "start": 1579,
                    "end": 1582,
                    "text": "(6)",
                    "ref_id": "BIBREF5"
                },
                {
                    "start": 1680,
                    "end": 1683,
                    "text": "(7)",
                    "ref_id": "BIBREF6"
                },
                {
                    "start": 1832,
                    "end": 1835,
                    "text": "(8)",
                    "ref_id": "BIBREF7"
                },
                {
                    "start": 2417,
                    "end": 2420,
                    "text": "(9,",
                    "ref_id": "BIBREF8"
                },
                {
                    "start": 2421,
                    "end": 2424,
                    "text": "10)",
                    "ref_id": "BIBREF9"
                }
            ],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "On the other hand, this repurposing strategy has some limitations, including patent barriers, the complexity of regulatory pathways, absence of funding opportunities, greater access to data from other industry-sponsored clinical trials, and the heterogeneity of the population for new clinical studies (10) . Nevertheless, drug repurposing is still a tool for the discovery of entirely new classes of medicines (10, 11) . Hence, considering this scenario, we felt that it is of interest to be aware of the drug repositioning in clinical tests for the COVID-2019 treatment.",
            "cite_spans": [
                {
                    "start": 302,
                    "end": 306,
                    "text": "(10)",
                    "ref_id": "BIBREF9"
                },
                {
                    "start": 411,
                    "end": 415,
                    "text": "(10,",
                    "ref_id": "BIBREF9"
                },
                {
                    "start": 416,
                    "end": 419,
                    "text": "11)",
                    "ref_id": "BIBREF10"
                }
            ],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "We performed a search on March 12, 2020, at the clinicaltrials. gov database, with the descriptor [coronavirus] in the simple search field \"conditions or disease\" search, without restrictions on languages, disease conditions, results, or locations. The eligibility criteria for the retrieved studies were: contain a clinicaltrials.gov base identifier number; describe the number of participants and the study period; describe the patient's clinical conditions; and interventions utilize medicines already studied or approved for any other disease in patients with COVID-19. ClinicalTrials.gov is a resource from the US National Library of Medicine, and it contains clinical studies conducted by 209 countries.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "METHODS"
        },
        {
            "text": "We identified 24 clinical trials ( Table 1) , in which 19 studies were at clinical phases 2, 3, or 4. The pharmaceutical interventions found for COVID-19 treatment include human immunoglobulin, interferons, chloroquine, hydroxychloroquine, arbidol, remdesivir, oseltamivir, favipiravir, carrimycin, methylprednisolone, bevacizumab, thalidomide, vitamin C, pirfenidone, bromhexine, fingolimod, danoprevir, ritonavir, darunavir, cobicistat, lopinavir, xiyanping, and traditional Chinese medicines (TCM).",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 35,
                    "end": 43,
                    "text": "Table 1)",
                    "ref_id": "TABREF0"
                }
            ],
            "section": "RESULTS AND DISCUSSION"
        },
        {
            "text": "Chloroquine and hydroxychloroquine are antimalarial drugs. They have antiviral effects against human immunodeficiency virus (HIV), namely by inhibiting virus entry into host cells. Another antiviral mechanism is related to the post-translation alteration of newly synthesized proteins via glycosylation inhibition (12) . Hydroxychloroquine is already being used in clinical trials on acquired immune deficiency syndrome (AIDS) treatment (13) . In a recent trial with patients on COVID-19 treatment (14) , 100% of patients treated with hydroxychloroquine in combination with the macrolide antibiotic azithromycin were virologically cured comparing with 57.1% in patients treated with hydroxychloroquine alone, and 12.5% in the control group. Currently, chloroquine and hydroxychloroquine will be tested (15, 16) in patients with pneumonia caused by 2019-nCoV and chloroquine as preventative medicine for COVID-19, as shown in Table 1 .",
            "cite_spans": [
                {
                    "start": 314,
                    "end": 318,
                    "text": "(12)",
                    "ref_id": "BIBREF11"
                },
                {
                    "start": 437,
                    "end": 441,
                    "text": "(13)",
                    "ref_id": null
                },
                {
                    "start": 498,
                    "end": 502,
                    "text": "(14)",
                    "ref_id": "BIBREF14"
                },
                {
                    "start": 802,
                    "end": 806,
                    "text": "(15,",
                    "ref_id": "BIBREF16"
                },
                {
                    "start": 807,
                    "end": 810,
                    "text": "16)",
                    "ref_id": null
                }
            ],
            "ref_spans": [
                {
                    "start": 925,
                    "end": 932,
                    "text": "Table 1",
                    "ref_id": "TABREF0"
                }
            ],
            "section": "RESULTS AND DISCUSSION"
        },
        {
            "text": "Immunoglobulins are useful in several diseases, such as idiopathic thrombocytopenia purpura (ITP), Guillain-Barre Syndrome (GBS), chronic inflammatory demyelinating polyneuropathy (CIDP), Kawasaki disease, and in multiple neurological autoimmune disorders refractory to standard immunosuppressive treatments (17) . Broadly neutralizing antibodies can recognize a wide variety of glycoproteins (GPs) in virus surfaces or the protein shell of a non-enveloped virus. However, HIV-1, dengue virus (DENV), influenza viruses, hepatitis C virus (HCV), and Ebola virus (EBOV) can mutate superficial GPs in order to evade the antibody response, an obstacle in the development of new therapies against such infections (18) . Trial NCT04261426 (19) is utilizing human immunoglobulin in patients with pneumonia caused by 2019-nCoV (Table 1) .",
            "cite_spans": [
                {
                    "start": 308,
                    "end": 312,
                    "text": "(17)",
                    "ref_id": "BIBREF19"
                },
                {
                    "start": 708,
                    "end": 712,
                    "text": "(18)",
                    "ref_id": "BIBREF20"
                }
            ],
            "ref_spans": [
                {
                    "start": 819,
                    "end": 828,
                    "text": "(Table 1)",
                    "ref_id": "TABREF0"
                }
            ],
            "section": "RESULTS AND DISCUSSION"
        },
        {
            "text": "Two clinical studies refer to the use of remdesivir in severe (20) or mild (21) respiratory infections by SARS-CoV-2. Remdesivir is a nucleotide analog inhibitor of the EBOV RNA-polymerase RNA-dependent (RdRp). Dyer et al. 2019 (22) described preliminary findings of a mortality rate of 33% in 499 patients treated with remdesivir against the EBOV disease in early infection stages. The same authors noted a mortality rate of 75% (almost 1 900 people) of non-treated infected patients during the same epidemic period (22) . Wang et al. 2020 (23) presented data showing that remdesivir is effective against the 2019-nCoV in Vero E6 cells (EC 90 1.76 \u03bcM). The suggested mechanism for remdesivir involves the host cells' post-entry stage (23) .",
            "cite_spans": [
                {
                    "start": 62,
                    "end": 66,
                    "text": "(20)",
                    "ref_id": null
                },
                {
                    "start": 228,
                    "end": 232,
                    "text": "(22)",
                    "ref_id": "BIBREF24"
                },
                {
                    "start": 517,
                    "end": 521,
                    "text": "(22)",
                    "ref_id": "BIBREF24"
                },
                {
                    "start": 541,
                    "end": 545,
                    "text": "(23)",
                    "ref_id": "BIBREF25"
                },
                {
                    "start": 735,
                    "end": 739,
                    "text": "(23)",
                    "ref_id": "BIBREF25"
                }
            ],
            "ref_spans": [],
            "section": "RESULTS AND DISCUSSION"
        },
        {
            "text": "Arbidol, also known as umifenovir, is approved in Russia and China for the treatment of influenza virus infections; it does not have significant adverse effects and is patented for SARS treatment (24) . As shown in Table 1 , four clinical trials will be conducted for COVID-19 treatment: one with arbidol in comparison with the basic treatment (25) , and the other three studies comparing effects with oseltamivir (26, 27) , lopinavirritonavir (27) , and carrimycin (28) . The arbidol anti-viral mechanism against influenza A and B involves viral fusion inhibition with the targeted membrane, which blocks virus entry into the cell (24) . Oseltamivir is another drug approved for influenza A and B treatment; it inhibits the viral neuraminidase and, consequently, blocks the release of viral particles from host cells, reducing the spread in the respiratory tract (29) . Additionally, the use of oseltamivir was already reported during the COVID-19 epidemic in China, either with or without antibiotics and corticosteroids (30) . Oseltamivir is also used in a clinical trial with multiple combinations with chloroquine and favipiravir (31), a nucleoside analog that is well-known as a broad-spectrum antiviral drug; it has shown (23) an EC 50 of 61.88 \u00b5M against SARS-CoV-2 and low toxicity (CC50 >400 \u00b5M).",
            "cite_spans": [
                {
                    "start": 196,
                    "end": 200,
                    "text": "(24)",
                    "ref_id": "BIBREF26"
                },
                {
                    "start": 344,
                    "end": 348,
                    "text": "(25)",
                    "ref_id": null
                },
                {
                    "start": 414,
                    "end": 418,
                    "text": "(26,",
                    "ref_id": null
                },
                {
                    "start": 419,
                    "end": 422,
                    "text": "27)",
                    "ref_id": null
                },
                {
                    "start": 444,
                    "end": 448,
                    "text": "(27)",
                    "ref_id": null
                },
                {
                    "start": 466,
                    "end": 470,
                    "text": "(28)",
                    "ref_id": null
                },
                {
                    "start": 632,
                    "end": 636,
                    "text": "(24)",
                    "ref_id": "BIBREF26"
                },
                {
                    "start": 864,
                    "end": 868,
                    "text": "(29)",
                    "ref_id": "BIBREF35"
                },
                {
                    "start": 1023,
                    "end": 1027,
                    "text": "(30)",
                    "ref_id": "BIBREF36"
                }
            ],
            "ref_spans": [
                {
                    "start": 215,
                    "end": 222,
                    "text": "Table 1",
                    "ref_id": "TABREF0"
                }
            ],
            "section": "RESULTS AND DISCUSSION"
        },
        {
            "text": "The lopinavir-ritonavir combination is approved for AIDS treatment in several countries. Both drugs are HIV protease inhibitors, but ritonavir is also a cytochrome P450 and GP inhibitor, a fact that endorses the lopinavir pharmacokinetic and pharmacodynamic activities against HIV (32) . Such a combination, plus b-1b interferon, is in phase 2 for the MERS treatment (33) . Several trials involve lopinavir-ritonavir treatment in comparison with the use of other drugs for COVID-19: (26, 27) , carrimycin (28) , TCM (34, 35) , xiyanping (36, 37) , danoprevir-ritonavir (38) and interferon inhalation (34, 38) . Nevertheless, one previous article argued that in a clinical trial with 199 patients with laboratory-confirmed SARS-CoV-2 infection, the lopinavir-ritonavir combination was not associated with clinical improvement comparing with standard care procedures (39) .",
            "cite_spans": [
                {
                    "start": 281,
                    "end": 285,
                    "text": "(32)",
                    "ref_id": "BIBREF39"
                },
                {
                    "start": 367,
                    "end": 371,
                    "text": "(33)",
                    "ref_id": "BIBREF40"
                },
                {
                    "start": 483,
                    "end": 487,
                    "text": "(26,",
                    "ref_id": null
                },
                {
                    "start": 488,
                    "end": 491,
                    "text": "27)",
                    "ref_id": null
                },
                {
                    "start": 505,
                    "end": 509,
                    "text": "(28)",
                    "ref_id": null
                },
                {
                    "start": 516,
                    "end": 520,
                    "text": "(34,",
                    "ref_id": null
                },
                {
                    "start": 521,
                    "end": 524,
                    "text": "35)",
                    "ref_id": null
                },
                {
                    "start": 537,
                    "end": 541,
                    "text": "(36,",
                    "ref_id": null
                },
                {
                    "start": 542,
                    "end": 545,
                    "text": "37)",
                    "ref_id": null
                },
                {
                    "start": 569,
                    "end": 573,
                    "text": "(38)",
                    "ref_id": null
                },
                {
                    "start": 600,
                    "end": 604,
                    "text": "(34,",
                    "ref_id": null
                },
                {
                    "start": 605,
                    "end": 608,
                    "text": "38)",
                    "ref_id": null
                },
                {
                    "start": 865,
                    "end": 869,
                    "text": "(39)",
                    "ref_id": "BIBREF51"
                }
            ],
            "ref_spans": [],
            "section": "RESULTS AND DISCUSSION"
        },
        {
            "text": "Carrimycin is a macrolide antibiotic with effects against some gram-positive bacteria and in vitro effects on Mycobacterium tuberculosis (40) .",
            "cite_spans": [
                {
                    "start": 137,
                    "end": 141,
                    "text": "(40)",
                    "ref_id": "BIBREF52"
                }
            ],
            "ref_spans": [],
            "section": "RESULTS AND DISCUSSION"
        },
        {
            "text": "Danoprevir is an HCV NS3 protease inhibitor approved in China for the treatment of non-cirrhotic genotype 1b chronic hepatitis C, in combination with ritonavir, peginterferon-a, and ribavirin (41) .",
            "cite_spans": [
                {
                    "start": 192,
                    "end": 196,
                    "text": "(41)",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "RESULTS AND DISCUSSION"
        },
        {
            "text": "Traditional Chinese medicine (TCM) uses phytotherapeutic formulations such as teas, pills, powders or tinctures, and cultural components that originated 5000 years ago in Chinese medicine (42) . TCMs were already used for SARS-CoV infection in 2002 as coadjuvant therapy with the enhancement of patients' symptoms, increased oxyhemoglobin arterial saturation; they proved useful in the early stages of this infection (42) .",
            "cite_spans": [
                {
                    "start": 188,
                    "end": 192,
                    "text": "(42)",
                    "ref_id": "BIBREF54"
                },
                {
                    "start": 417,
                    "end": 421,
                    "text": "(42)",
                    "ref_id": "BIBREF54"
                }
            ],
            "ref_spans": [],
            "section": "RESULTS AND DISCUSSION"
        },
        {
            "text": "Interferons (IFNs) are proteins that bind to cellular surfaces' receptors and initiate JAK-STAT signaling cascades, with transcriptional regulation of genes controlled by interferons and effects against some viruses like hepatitis B virus and HCV (43) .",
            "cite_spans": [
                {
                    "start": 247,
                    "end": 251,
                    "text": "(43)",
                    "ref_id": "BIBREF55"
                }
            ],
            "ref_spans": [],
            "section": "RESULTS AND DISCUSSION"
        },
        {
            "text": "Xiyanping is a TCM preparation with andrographolide as a principal component; it has significant antibacterial and antiviral effects (44) .",
            "cite_spans": [
                {
                    "start": 133,
                    "end": 137,
                    "text": "(44)",
                    "ref_id": "BIBREF56"
                }
            ],
            "ref_spans": [],
            "section": "RESULTS AND DISCUSSION"
        },
        {
            "text": "Darunavir, in combination with cobicistat, will be used in trial number NCT04252274 (45) in patients with COVID-19 pneumonia. The United States Food and Drug Administration (FDA) currently approves such a combination in AIDS treatment. Darunavir is another HIV protease inhibitor, and cobicistat, like ritonavir, is a booster for enhancing the pharmacokinetics and pharmacodynamics of darunavir by cytochrome P450 (CYP3A) inhibition (46, 47) .",
            "cite_spans": [
                {
                    "start": 84,
                    "end": 88,
                    "text": "(45)",
                    "ref_id": null
                },
                {
                    "start": 433,
                    "end": 437,
                    "text": "(46,",
                    "ref_id": "BIBREF59"
                },
                {
                    "start": 438,
                    "end": 441,
                    "text": "47)",
                    "ref_id": "BIBREF60"
                }
            ],
            "ref_spans": [],
            "section": "RESULTS AND DISCUSSION"
        },
        {
            "text": "Recombinant human interferon a2b is described to have inhibitory effects on MERS-CoV and SARS-CoV (48) , and the purpose of the clinical trials found for this paper is to evaluate the efficacy and safety of recombinant human interferon a2b in treating patients with new coronavirus infection (49) .",
            "cite_spans": [
                {
                    "start": 98,
                    "end": 102,
                    "text": "(48)",
                    "ref_id": null
                },
                {
                    "start": 292,
                    "end": 296,
                    "text": "(49)",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "RESULTS AND DISCUSSION"
        },
        {
            "text": "Thalidomide will be used in two trials against COVID-19 (49, 50) . Thalidomide has an anti-inflammatory action due to its ability to speed up the degradation of messenger RNA in blood cells and thus reduce tumor necrosis factor-a (TNFa). Furthermore, thalidomide can increase the secretion of interleukins, such as IL-12, and activate natural killer cells (51) .",
            "cite_spans": [
                {
                    "start": 56,
                    "end": 60,
                    "text": "(49,",
                    "ref_id": null
                },
                {
                    "start": 61,
                    "end": 64,
                    "text": "50)",
                    "ref_id": null
                },
                {
                    "start": 356,
                    "end": 360,
                    "text": "(51)",
                    "ref_id": "BIBREF67"
                }
            ],
            "ref_spans": [],
            "section": "RESULTS AND DISCUSSION"
        },
        {
            "text": "The corticosteroid methylprednisolone will be tested against COVID-19 (52). Long et al. 2016 (53) reported that corticosteroid therapy (methylprednisolone, dexamethasone, and hydrocortisone) is beneficial in treating SARS-CoV patients; it significantly prolongs the survival time of clinical cases. Nevertheless, other authors described the use of corticosteroids in the early stages of SARS infection with increasing values of viral load (54) . Furthermore, studies with corticosteroids in the adjuvant therapy of MERS-CoV infection were unable to prove efficacy because all patients died (55) . Methylprednisolone has already been used in COVID-19 patients in combination with antibiotics, oseltamivir, and oxygen therapy (56) .",
            "cite_spans": [
                {
                    "start": 76,
                    "end": 97,
                    "text": "Long et al. 2016 (53)",
                    "ref_id": null
                },
                {
                    "start": 439,
                    "end": 443,
                    "text": "(54)",
                    "ref_id": "BIBREF71"
                },
                {
                    "start": 590,
                    "end": 594,
                    "text": "(55)",
                    "ref_id": "BIBREF72"
                },
                {
                    "start": 724,
                    "end": 728,
                    "text": "(56)",
                    "ref_id": "BIBREF73"
                }
            ],
            "ref_spans": [],
            "section": "RESULTS AND DISCUSSION"
        },
        {
            "text": "Finally, vitamin C (ascorbic acid), pirfenidone, bevacizumab, fingolimod, and bromhexine hydrochloride are going to be tested on COVID-19 (57) (58) (59) (60) (61) . Vitamin C has antioxidant activity and may reduce oxidative stress and inflammation (57, 62) , effects that improve vasopressor synthesis, enhance immune cell function, improve endovascular function, and provide epigenetic immunologic modifications. Clinical trials have demonstrated promising data on mortality improvement in sepsis, but more extensive studies are necessary to validate these conclusions (63) . Pirfenidone has been used in the treatment of idiopathic pulmonary fibrosis diseases due to anti-inflammatory and anti-oxidant effects, namely by inhibiting IL-1b and IL-4 (58) . Trial NCT04282902 claimed (58) that anti-inflammatory effects may be helpful in SARS-CoV-2 infection. Bevacizumab is a humanized monoclonal antibody that targets vascular endothelial growth factor (VEGF) (59, 63) , and it may reduce the levels of VEGF caused by hypoxia, severe inflammation, and upregulation of the infected respiratory tract epithelium, all of which might suppress the edema in patients with COVID-19 (63) . Fingolimod is a sphingosine-1-phosphate receptor regulator (FTY720) with an effective immunology modulator that is useful in multiple sclerosis (60) . According to some pathological findings of pulmonary edema and hyaline membrane formation, the use of immune modulators, together with ventilator support, should be considered for severe patients to prevent the development of acute respiratory distress syndrome (ARDS). Study NCT04280588 aims to determine the efficacy of fingolimod for COVID-19 (60). Bromhexine is a transmembrane protease serine inhibitor; such a protease is responsible for the activation of S-glycoprotein of SARS-CoV and MERS-CoV for viral entry through the plasma membrane (61, 64) . One study (60) will evaluate the efficacy of bromhexine combined with standard treatment/standard treatment in patients with COVID-19.",
            "cite_spans": [
                {
                    "start": 138,
                    "end": 142,
                    "text": "(57)",
                    "ref_id": null
                },
                {
                    "start": 143,
                    "end": 147,
                    "text": "(58)",
                    "ref_id": null
                },
                {
                    "start": 148,
                    "end": 152,
                    "text": "(59)",
                    "ref_id": null
                },
                {
                    "start": 153,
                    "end": 157,
                    "text": "(60)",
                    "ref_id": null
                },
                {
                    "start": 158,
                    "end": 162,
                    "text": "(61)",
                    "ref_id": null
                },
                {
                    "start": 249,
                    "end": 253,
                    "text": "(57,",
                    "ref_id": null
                },
                {
                    "start": 254,
                    "end": 257,
                    "text": "62)",
                    "ref_id": "BIBREF84"
                },
                {
                    "start": 571,
                    "end": 575,
                    "text": "(63)",
                    "ref_id": "BIBREF85"
                },
                {
                    "start": 750,
                    "end": 754,
                    "text": "(58)",
                    "ref_id": null
                },
                {
                    "start": 961,
                    "end": 965,
                    "text": "(59,",
                    "ref_id": null
                },
                {
                    "start": 966,
                    "end": 969,
                    "text": "63)",
                    "ref_id": "BIBREF85"
                },
                {
                    "start": 1176,
                    "end": 1180,
                    "text": "(63)",
                    "ref_id": "BIBREF85"
                },
                {
                    "start": 1327,
                    "end": 1331,
                    "text": "(60)",
                    "ref_id": null
                },
                {
                    "start": 1880,
                    "end": 1884,
                    "text": "(61,",
                    "ref_id": null
                },
                {
                    "start": 1885,
                    "end": 1888,
                    "text": "64)",
                    "ref_id": "BIBREF86"
                },
                {
                    "start": 1901,
                    "end": 1905,
                    "text": "(60)",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "RESULTS AND DISCUSSION"
        },
        {
            "text": "In conclusion, the WHO declared an epidemic of pneumonia caused by the SARS-CoV-2 in 2020. In this review, we found 24 clinical trials that have already started with the repositioning of more than 20 medicines for COVID-19 treatment, such as human immunoglobulin, interferons, chloroquine, hydroxychloroquine, arbidol, remdesivir, favipiravir, oseltamivir, thalidomide, methylprednisolone, bevacizumab, and TCM. The Hydroxychloroquine-azithromycin combination was the first drug repurposed with excellent results in clinical trials against SARS-CoV-2, but further, more extended studies, with a higher number of patients, are needed to confirm these results. Besides its limitations, repositioning clinical trials are still an attractive strategy: they may facilitate the discovery of new classes of medicines; they may reduce the costs and time to reach the market; there is an existing pharmaceutical supply chain for formulation and distribution; and there is the possibility of combinations with other drugs in treatments that are more effective than monotherapy. Most of the studies found in this article are scheduled to end in 2020, and we hope these repositioning trials may help to find solutions for COVID-19 treatment by this year.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "RESULTS AND DISCUSSION"
        },
        {
            "text": "Disclaimer. Authors hold sole responsibility for the views expressed in the manuscript, which may not necessarily reflect the opinion or policy of the RPSP/PAJPH and/or PAHO. ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Conflicts of interest. None declared."
        }
    ],
    "bib_entries": {
        "BIBREF0": {
            "ref_id": "b0",
            "title": "Novel Coronavirus (2019-nCoV) Situation Report -52. Data as reported by 12",
            "authors": [],
            "year": 2020,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF1": {
            "ref_id": "b1",
            "title": "Editorial -Novel Coronavirus 2019 (Sars-CoV2): a global emergency that needs new approaches?",
            "authors": [
                {
                    "first": "A",
                    "middle": [],
                    "last": "Perrella",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Carannante",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Berretta",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Rinaldi",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Maturo",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Rinaldi",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Eur Rev Med Pharmaco",
            "volume": "24",
            "issn": "",
            "pages": "2162--2164",
            "other_ids": {}
        },
        "BIBREF2": {
            "ref_id": "b2",
            "title": "Novel Coronavirus-Important Information for Clinicians",
            "authors": [
                {
                    "first": "C",
                    "middle": [],
                    "last": "Del Rio",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [
                        "N"
                    ],
                    "last": "Malani",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "JAMA",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1001/jama.2020.1490"
                ]
            }
        },
        "BIBREF3": {
            "ref_id": "b3",
            "title": "A Novel Coronavirus from Patients with Pneumonia in China",
            "authors": [
                {
                    "first": "N",
                    "middle": [],
                    "last": "Zhu",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Yang",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Song",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "N Engl J Med",
            "volume": "",
            "issn": "",
            "pages": "1--7",
            "other_ids": {}
        },
        "BIBREF4": {
            "ref_id": "b4",
            "title": "Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People's Republic of China",
            "authors": [
                {
                    "first": "N",
                    "middle": [
                        "S"
                    ],
                    "last": "Zhong",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [
                        "J"
                    ],
                    "last": "Zheng",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [
                        "M"
                    ],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "Llm",
                    "middle": [],
                    "last": "Poon",
                    "suffix": ""
                },
                {
                    "first": "Z",
                    "middle": [
                        "H"
                    ],
                    "last": "Xie",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [
                        "H"
                    ],
                    "last": "Chan",
                    "suffix": ""
                }
            ],
            "year": 2003,
            "venue": "Lancet",
            "volume": "362",
            "issn": "9393",
            "pages": "1353--1361",
            "other_ids": {}
        },
        "BIBREF5": {
            "ref_id": "b5",
            "title": "Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection: epidemiology, pathogenesis and clinical characteristics",
            "authors": [
                {
                    "first": "M",
                    "middle": [
                        "S"
                    ],
                    "last": "Nassar",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "A"
                    ],
                    "last": "Bakhrebah",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "A"
                    ],
                    "last": "Meo",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "S"
                    ],
                    "last": "Alsuabeyl",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [
                        "A"
                    ],
                    "last": "Zaher",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "Eur Rev Med Pharmaco",
            "volume": "22",
            "issn": "15",
            "pages": "4956--61",
            "other_ids": {}
        },
        "BIBREF6": {
            "ref_id": "b6",
            "title": "Therapeutic options for the 2019 novel coronavirus (2019-nCoV)",
            "authors": [
                {
                    "first": "G",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "De",
                    "middle": [],
                    "last": "Clercq",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "Nat Rev Drug Discov",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF7": {
            "ref_id": "b7",
            "title": "Slew of trials launch to test coronavirus treatments in China",
            "authors": [
                {
                    "first": "A",
                    "middle": [],
                    "last": "Maxmen",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Nature",
            "volume": "78",
            "issn": "",
            "pages": "37--348",
            "other_ids": {}
        },
        "BIBREF8": {
            "ref_id": "b8",
            "title": "Drug Repurposing for Viral Infectious Diseases: How Far Are We?",
            "authors": [
                {
                    "first": "B",
                    "middle": [],
                    "last": "Mercorelli",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Pal\u00f9",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Loregian",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "Trends Microbiol",
            "volume": "26",
            "issn": "10",
            "pages": "865--876",
            "other_ids": {
                "DOI": [
                    "10.1016/j.tim.2018.04.004"
                ]
            }
        },
        "BIBREF9": {
            "ref_id": "b9",
            "title": "Drug repurposing: progress, challenges and recommendations",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Pushpakom",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Iorio",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [
                        "A"
                    ],
                    "last": "Eyers",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [
                        "J"
                    ],
                    "last": "Escott",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Hopper",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Wells",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "Nat Rev Drug Discov",
            "volume": "18",
            "issn": "1",
            "pages": "41--58",
            "other_ids": {}
        },
        "BIBREF10": {
            "ref_id": "b10",
            "title": "Renovation as innovation: is repurposing the future of drug discovery research?",
            "authors": [
                {
                    "first": "A",
                    "middle": [],
                    "last": "Neuberger",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Oraiopoulos",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "L"
                    ],
                    "last": "Drakeman",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "Drug Discov Today",
            "volume": "24",
            "issn": "1",
            "pages": "1--3",
            "other_ids": {
                "DOI": [
                    "10.1016/j.drudis.2018.06.012"
                ]
            }
        },
        "BIBREF11": {
            "ref_id": "b11",
            "title": "Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "M"
                    ],
                    "last": "Rolain",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Colson",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Raoult",
                    "suffix": ""
                }
            ],
            "year": 2007,
            "venue": "Int J Antimicrob Agents",
            "volume": "30",
            "issn": "4",
            "pages": "297--308",
            "other_ids": {}
        },
        "BIBREF13": {
            "ref_id": "b13",
            "title": "2020 Feb 18 -Identifier NCT01067417, Evaluation of the Efficacy of Hydroxychloroquine in Decreasing Immune activation in asymptomatic HIV-infected patients (HCQ01)",
            "authors": [
                {
                    "first": "(",
                    "middle": [],
                    "last": "Bethesda",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Md",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF14": {
            "ref_id": "b14",
            "title": "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial",
            "authors": [
                {
                    "first": "P",
                    "middle": [],
                    "last": "Gautret",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "C"
                    ],
                    "last": "Lagier",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Parola",
                    "suffix": ""
                },
                {
                    "first": "V",
                    "middle": [
                        "T"
                    ],
                    "last": "Hoang",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Meddeb",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Mailhe",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF16": {
            "ref_id": "b16",
            "title": "2020 Mar 12 -Identifier NCT04303507, Chloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting (COPCOV)",
            "authors": [
                {
                    "first": "(",
                    "middle": [],
                    "last": "Bethesda",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Md",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF18": {
            "ref_id": "b18",
            "title": "2020 Mar 12 -Identifier NCT04261517. Efficacy and Safety of Hydroxychloroquine for Treatment of Pneumonia Caused by 2019-nCoV (HC-nCoV)",
            "authors": [
                {
                    "first": "(",
                    "middle": [],
                    "last": "Bethesda",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Md",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF19": {
            "ref_id": "b19",
            "title": "Management of adverse events in the treatment of patients with immunoglobulin therapy: A review of evidence",
            "authors": [
                {
                    "first": "P",
                    "middle": [],
                    "last": "Cherin",
                    "suffix": ""
                },
                {
                    "first": "Marie",
                    "middle": [
                        "I"
                    ],
                    "last": "Michallet",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Pelus",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "Dantal",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Crave",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "C"
                    ],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": 2016,
            "venue": "Autoimmun Rev",
            "volume": "15",
            "issn": "1",
            "pages": "71--81",
            "other_ids": {
                "DOI": [
                    "10.1016/j.autrev.2015.09.002"
                ]
            }
        },
        "BIBREF20": {
            "ref_id": "b20",
            "title": "Broadly neutralizing antibodies for therapy of viral infections",
            "authors": [
                {
                    "first": "R",
                    "middle": [],
                    "last": "Varadarajan",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Srinivasan",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Maity",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Ghosh",
                    "suffix": ""
                }
            ],
            "year": 2016,
            "venue": "Antib Technol J",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF21": {
            "ref_id": "b21",
            "title": "2020 Mar 12 -Identifier NCT04261426, The Efficacy of Intravenous Immunoglobulin Therapy for Severe 2019-nCoV infected pneumonia",
            "authors": [
                {
                    "first": "(",
                    "middle": [],
                    "last": "Bethesda",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Md",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF23": {
            "ref_id": "b23",
            "title": "2020 Mar 12 -Identifier NCT04257656, Severe2019-nCoV Remdesivir RCT",
            "authors": [
                {
                    "first": "(",
                    "middle": [],
                    "last": "Bethesda",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Md",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "NCT04252664. Mild / Moderate 2019-nCoV Remdesivir RCT. Available from",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF24": {
            "ref_id": "b24",
            "title": "Two Ebola treatments halve deaths in trial in DRC outbreak",
            "authors": [
                {
                    "first": "O",
                    "middle": [],
                    "last": "Dyer",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "BMJ",
            "volume": "366",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1136/bmj.l5140"
                ]
            }
        },
        "BIBREF25": {
            "ref_id": "b25",
            "title": "Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Cao",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Yang",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Xu",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Cell Res",
            "volume": "",
            "issn": "",
            "pages": "2019--2040",
            "other_ids": {}
        },
        "BIBREF26": {
            "ref_id": "b26",
            "title": "Arbidol as a broad-spectrum antiviral: An update",
            "authors": [
                {
                    "first": "J",
                    "middle": [],
                    "last": "Blaising",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "J"
                    ],
                    "last": "Polyak",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [
                        "I"
                    ],
                    "last": "P\u00e9cheur",
                    "suffix": ""
                }
            ],
            "year": 2014,
            "venue": "Antiviral Res",
            "volume": "107",
            "issn": "1",
            "pages": "84--94",
            "other_ids": {
                "DOI": [
                    "10.1016/j.antiviral.2014.04.006"
                ]
            }
        },
        "BIBREF28": {
            "ref_id": "b28",
            "title": "2020 Mar 12 -Identifier NCT04260594, Clinical Study of Arbidol Hydrochloride Tablets in the Treatment of Pneumonia Caused by Novel Coronavirus",
            "authors": [
                {
                    "first": "(",
                    "middle": [],
                    "last": "Bethesda",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Md",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF30": {
            "ref_id": "b30",
            "title": "2020 Mar 12 -Identifier NCT04255017, A prospective, randomized controlled clinical study of antiviral therapy in the 2019-nCoV pneumonia",
            "authors": [
                {
                    "first": "(",
                    "middle": [],
                    "last": "Bethesda",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Md",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF32": {
            "ref_id": "b32",
            "title": "2020 Mar 12 -Identifier NCT04252885, The efficacy of lopinavir plus ritonavir and arbidol against novel coronavirus infection (ELACOI)",
            "authors": [
                {
                    "first": "(",
                    "middle": [],
                    "last": "Bethesda",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Md",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF34": {
            "ref_id": "b34",
            "title": "2020 Mar 12 -Identifier NCT04286503, The clinical study of carrimycin on treatment patients with Covid-19",
            "authors": [
                {
                    "first": "(",
                    "middle": [],
                    "last": "Bethesda",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Md",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF35": {
            "ref_id": "b35",
            "title": "Oseltamivir Treatment of Influenza in Children",
            "authors": [
                {
                    "first": "T",
                    "middle": [
                        "M"
                    ],
                    "last": "Uyeki",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "Clin Infect Dis",
            "volume": "66",
            "issn": "10",
            "pages": "1501--1504",
            "other_ids": {}
        },
        "BIBREF36": {
            "ref_id": "b36",
            "title": "Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China",
            "authors": [
                {
                    "first": "D",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Hu",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Hu",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Zhu",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "JAMA",
            "volume": "7",
            "issn": "",
            "pages": "1--9",
            "other_ids": {}
        },
        "BIBREF38": {
            "ref_id": "b38",
            "title": "2020 Mar 12 -Identifier NCT04303299, Various combination of Protease Inhibitors, Oseltamivir, Favipiravir, and Chloroquin for Treatment of COVID-19: A Randomized Control Trial",
            "authors": [
                {
                    "first": "(",
                    "middle": [],
                    "last": "Bethesda",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Md",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF39": {
            "ref_id": "b39",
            "title": "Lopinavir-ritonavir combination induces endoplasmic reticulum stress and kills urological cancer cells",
            "authors": [
                {
                    "first": "K",
                    "middle": [],
                    "last": "Okubo",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Isono",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Asano",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Sato",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "Anticancer Res",
            "volume": "39",
            "issn": "11",
            "pages": "5891--901",
            "other_ids": {}
        },
        "BIBREF40": {
            "ref_id": "b40",
            "title": "Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-b1b (MIRA-CLE trial): Study protocol for a randomized controlled trial",
            "authors": [
                {
                    "first": "Y",
                    "middle": [
                        "M"
                    ],
                    "last": "Arabi",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Alothman",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [
                        "H"
                    ],
                    "last": "Balkhy",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Al-Dawood",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Aljohani",
                    "suffix": ""
                },
                {
                    "first": "Al",
                    "middle": [],
                    "last": "Harbi",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "Trials",
            "volume": "19",
            "issn": "1",
            "pages": "1--13",
            "other_ids": {}
        },
        "BIBREF42": {
            "ref_id": "b42",
            "title": "2020 Mar 12 -Identifier NCT04251871, Treatment and prevention of traditional Chinese medicines (TCMs) on 2019-nCoV infection",
            "authors": [
                {
                    "first": "(",
                    "middle": [],
                    "last": "Bethesda",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Md",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF44": {
            "ref_id": "b44",
            "title": "2020 Mar 12 -Identifier NCT04251871, Treatment and Prevention of Traditional Chinese Medicines (TCMs) on2019-nCoV Infection",
            "authors": [
                {
                    "first": "(",
                    "middle": [],
                    "last": "Bethesda",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Md",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF46": {
            "ref_id": "b46",
            "title": "2020 Mar 12 -Identifier NCT04275388, Xiyanping injection for the treatment of new coronavirus infected pneumonia",
            "authors": [
                {
                    "first": "(",
                    "middle": [],
                    "last": "Bethesda",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Md",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF48": {
            "ref_id": "b48",
            "title": "2020 Mar 12 -Identifier NCT04295551, Multicenter clinical study on the efficacy and safety of Xiyanping injection in the treatment of the new coronavirus infection pneumonia (general and severe",
            "authors": [
                {
                    "first": "(",
                    "middle": [],
                    "last": "Bethesda",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Md",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF50": {
            "ref_id": "b50",
            "title": "2020 Mar 12 -Identifier NCT04291729, Evaluation of Ganovo (danoprevir) combined with ritonavir in the treatment of the novel coronavirus infection",
            "authors": [
                {
                    "first": "(",
                    "middle": [],
                    "last": "Bethesda",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Md",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF51": {
            "ref_id": "b51",
            "title": "A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19",
            "authors": [
                {
                    "first": "B",
                    "middle": [],
                    "last": "Cao",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "1--13",
            "other_ids": {
                "DOI": [
                    "10.1056/NEJMoa2001282"
                ]
            }
        },
        "BIBREF52": {
            "ref_id": "b52",
            "title": "Use of carrimycin in Mycobacterium tuberculosis infection resistance",
            "authors": [
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Jiang",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Zhao",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [],
                    "last": "He",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF54": {
            "ref_id": "b54",
            "title": "Application of Chinese Medicine in Acute and Critical Medical Conditions",
            "authors": [
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Luo",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "Z"
                    ],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Hesse-Fong",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "G"
                    ],
                    "last": "Lin",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "S"
                    ],
                    "last": "Yuan",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "Am J Chin Med",
            "volume": "47",
            "issn": "6",
            "pages": "1223--1258",
            "other_ids": {}
        },
        "BIBREF55": {
            "ref_id": "b55",
            "title": "Interferon-Stimulated Genes: A Complex Web of Host Defenses NIH Public Access",
            "authors": [
                {
                    "first": "W",
                    "middle": [
                        "M"
                    ],
                    "last": "Schneider",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "D"
                    ],
                    "last": "Chevillotte",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "M"
                    ],
                    "last": "Rice",
                    "suffix": ""
                }
            ],
            "year": 2015,
            "venue": "",
            "volume": "32",
            "issn": "",
            "pages": "513--558",
            "other_ids": {
                "DOI": [
                    "10.1146/annurev-immunol-032713-120231"
                ]
            }
        },
        "BIBREF56": {
            "ref_id": "b56",
            "title": "Application of Xiyanping in treatment of infantile rotavirus diarrhea",
            "authors": [
                {
                    "first": "T",
                    "middle": [],
                    "last": "Tang",
                    "suffix": ""
                }
            ],
            "year": 2016,
            "venue": "J Hainan Med Univ",
            "volume": "22",
            "issn": "13",
            "pages": "113--118",
            "other_ids": {}
        },
        "BIBREF58": {
            "ref_id": "b58",
            "title": "2020 Mar 12 -Identifier NCT04252274. Efficacy and Safety of Darunavir and Cobicistat for Treatment of Pneumonia Caused by 2019-nCoV (DACO-nCoV)",
            "authors": [
                {
                    "first": "(",
                    "middle": [],
                    "last": "Bethesda",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Md",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF59": {
            "ref_id": "b59",
            "title": "Simplification of Antiretroviral Treatment from Darunavir/Ritonavir Monotherapy to Darunavir/Cobicistat Monotherapy: Effectiveness and Safety in Routine Clinical Practice",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "R"
                    ],
                    "last": "Santos",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Curran",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Navarro-Mercade",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "F"
                    ],
                    "last": "Ampuero",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Pelaez",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "P\u00e9rez-Alvarez",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "AIDS Res Hum Retroviruses",
            "volume": "35",
            "issn": "6",
            "pages": "513--521",
            "other_ids": {}
        },
        "BIBREF60": {
            "ref_id": "b60",
            "title": "Pharmacokinetics and Pharmacodynamics of cobicistat GS-9350: A Novel Pharmacokinetic Enhancer Without Anti-HIV Activity",
            "authors": [
                {
                    "first": "A",
                    "middle": [
                        "A"
                    ],
                    "last": "Mathias",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "German",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [
                        "P"
                    ],
                    "last": "Murray",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Wei",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Jain",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "West",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Warren",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Hui",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [
                        "P"
                    ],
                    "last": "Kearney",
                    "suffix": ""
                }
            ],
            "year": 2010,
            "venue": "Clin Pharmacol Ther",
            "volume": "87",
            "issn": "3",
            "pages": "322--329",
            "other_ids": {
                "DOI": [
                    "10.1038/clpt.2009.228"
                ]
            }
        },
        "BIBREF62": {
            "ref_id": "b62",
            "title": "2020 Mar 12 -Identifier NCT04293887, Efficacy and safety of IFN-a2b in the treatment of novel coronavirus patients",
            "authors": [
                {
                    "first": "(",
                    "middle": [],
                    "last": "Bethesda",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Md",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF64": {
            "ref_id": "b64",
            "title": "2020 Mar 12 -Identifier NCT04273581, The efficacy and safety of thalidomide combined with low-dose hormones in the treatment of severe Covid-19",
            "authors": [
                {
                    "first": "(",
                    "middle": [],
                    "last": "Bethesda",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Md",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF66": {
            "ref_id": "b66",
            "title": "2020 Mar 12 -Identifier NCT04273529, The efficacy and safety of thalidomide in the adjuvant treatment of moderate new coronavirus (Covid-19) pneumonia",
            "authors": [
                {
                    "first": "(",
                    "middle": [],
                    "last": "Bethesda",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Md",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF67": {
            "ref_id": "b67",
            "title": "New Medical Indications for Thalidomide and its Derivatives New Medical Indications for Thalidomide and its Derivatives",
            "authors": [
                {
                    "first": "C",
                    "middle": [],
                    "last": "Newfield",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "The Science Journal of the Lander College of Arts and Sciences",
            "volume": "12",
            "issn": "1",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF69": {
            "ref_id": "b69",
            "title": "2020 Mar 12 -Identifier NCT04244591. Glucocorticoid Therapy for Novel Coronavirus Critically Ill Patients With Severe Acute Respiratory Failure (Steroids-SARI)",
            "authors": [
                {
                    "first": "(",
                    "middle": [],
                    "last": "Bethesda",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Md",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF70": {
            "ref_id": "b70",
            "title": "Clinical recommendations from an observational study on MERS: Glucocorticoids was benefit in treating SARS patients",
            "authors": [
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Long",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Xu",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Jia",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Xue",
                    "suffix": ""
                }
            ],
            "year": 2016,
            "venue": "Int J Clin Exp Med",
            "volume": "9",
            "issn": "5",
            "pages": "8865--73",
            "other_ids": {}
        },
        "BIBREF71": {
            "ref_id": "b71",
            "title": "Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients",
            "authors": [
                {
                    "first": "N",
                    "middle": [],
                    "last": "Lee",
                    "suffix": ""
                },
                {
                    "first": "Allen",
                    "middle": [],
                    "last": "Chan",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [
                        "C"
                    ],
                    "last": "Hui",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "S"
                    ],
                    "last": "Ng",
                    "suffix": ""
                },
                {
                    "first": "Eko",
                    "middle": [],
                    "last": "Wu",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Chiu",
                    "suffix": ""
                },
                {
                    "first": "Rwk",
                    "middle": [],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": 2004,
            "venue": "J Clin Virol",
            "volume": "31",
            "issn": "4",
            "pages": "304--313",
            "other_ids": {}
        },
        "BIBREF72": {
            "ref_id": "b72",
            "title": "Update on therapeutic options for Middle East Respiratory Syndrome Coronavirus (MERS-CoV)",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "A"
                    ],
                    "last": "Al-Tawfiq",
                    "suffix": ""
                },
                {
                    "first": "Z",
                    "middle": [
                        "A"
                    ],
                    "last": "Memish",
                    "suffix": ""
                }
            ],
            "year": 2017,
            "venue": "Expert Rev Anti Infect Ther",
            "volume": "15",
            "issn": "3",
            "pages": "269--75",
            "other_ids": {
                "DOI": [
                    "10.1080/14787210.2017.1271712"
                ]
            }
        },
        "BIBREF73": {
            "ref_id": "b73",
            "title": "Clinical features of patients infected with 2019 novel coronavirus in Wuhan",
            "authors": [
                {
                    "first": "C",
                    "middle": [],
                    "last": "Huang",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Ren",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Zhao",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Hu",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "China. Lancet",
            "volume": "",
            "issn": "",
            "pages": "497--506",
            "other_ids": {}
        },
        "BIBREF75": {
            "ref_id": "b75",
            "title": "2020 Mar 12 -Identifier NCT04264533, Vitamina C infusion for the treatment of severe 2019-nCoV infected pneumonia",
            "authors": [
                {
                    "first": "(",
                    "middle": [],
                    "last": "Bethesda",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Md",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF77": {
            "ref_id": "b77",
            "title": "2020 Mar 12 -Identifier NCT04282902, A study to evaluate the efficacy and safety of Pirfenidone with novel coronavirus infection",
            "authors": [
                {
                    "first": "(",
                    "middle": [],
                    "last": "Bethesda",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Md",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF79": {
            "ref_id": "b79",
            "title": "2020 Mar 12 -Identifier NCT04275414, Bevacizumab in severe or critical patients with Covid-19 pneumonia (BEST-CP)",
            "authors": [
                {
                    "first": "(",
                    "middle": [],
                    "last": "Bethesda",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Md",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF81": {
            "ref_id": "b81",
            "title": "2020 Mar 12 -Identifier NCT04280588, Fingolimod in COVID-19",
            "authors": [
                {
                    "first": "(",
                    "middle": [],
                    "last": "Bethesda",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Md",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF83": {
            "ref_id": "b83",
            "title": "2020 Mar 12 -Identifier NCT04273763, Evaluating the efficacy and safety of bromhexine hydrochloride tablets combined with standard treatment/standard treatment in patients with suspected and mild coronavirus pneumonia (COVID-19)",
            "authors": [
                {
                    "first": "(",
                    "middle": [],
                    "last": "Bethesda",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Md",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF84": {
            "ref_id": "b84",
            "title": "The emerging role of vitamin C as a treatment for sepsis",
            "authors": [
                {
                    "first": "M",
                    "middle": [
                        "G"
                    ],
                    "last": "Kashiouris",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "&apos;heureux",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Cable",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "A"
                    ],
                    "last": "Fisher",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [
                        "J"
                    ],
                    "last": "Leichtle",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "W"
                    ],
                    "last": "Fowler",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "A"
                    ],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Nutrients",
            "volume": "12",
            "issn": "2",
            "pages": "1--16",
            "other_ids": {}
        },
        "BIBREF85": {
            "ref_id": "b85",
            "title": "Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro",
            "authors": [
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Fei",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Vanderlaan",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Song",
                    "suffix": ""
                }
            ],
            "year": 2004,
            "venue": "Angiogenesis",
            "volume": "7",
            "issn": "4",
            "pages": "335--380",
            "other_ids": {}
        },
        "BIBREF86": {
            "ref_id": "b86",
            "title": "Repurposing host-based therapeutics to control coronavirus and influenza virus",
            "authors": [
                {
                    "first": "C",
                    "middle": [
                        "C"
                    ],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [
                        "J"
                    ],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "Hcr",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "Drug Discov Today",
            "volume": "24",
            "issn": "3",
            "pages": "726--762",
            "other_ids": {
                "DOI": [
                    "10.1016/j.drudis.2019.01.018"
                ]
            }
        },
        "BIBREF87": {
            "ref_id": "b87",
            "title": "Revised version accepted for publication on",
            "authors": [],
            "year": 2020,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        }
    },
    "ref_entries": {
        "TABREF0": {
            "text": "Clinical trials identified at Clinicaltrials.gov related to drug repositioning for COVID-19 treatment",
            "latex": null,
            "type": "table"
        },
        "TABREF1": {
            "text": "Ensayos cl\u00ednicos de reposicionamiento de medicamentos para el tratamiento de la COVID-19RESUMEN   En diciembre de 2019 fue informado a la Organizaci\u00f3n Mundial de la Salud (OMS) un brote de neumon\u00eda por coronavirus en Wuhan, provincia de Hubei, China. Al 12 de marzo de 2020, se hab\u00edan notificado 125 048 casos y 4 614 muertes. El coronavirus es un virus ARN envuelto del g\u00e9nero Betacoronavirus distribuido en aves, seres humanos y otros mam\u00edferos. La OMS ha denominado a la nueva enfermedad por coronavirus COVID-19. Se han puesto en marcha m\u00e1s de 80 ensayos cl\u00ednicos para evaluar un tratamiento para el coronavirus, que incluyen algunos ensayos de reposicionamiento de medicamentos para la COVID-19. En marzo de 2020 se llev\u00f3 a cabo una b\u00fasqueda de los ensayos cl\u00ednicos registrados en la base de datos clinicaltrials.gov. Los criterios de elegibilidad para los estudios recuperados fueron tener un n\u00famero de identificaci\u00f3n de la base de datos clinicaltrials.gov; describir el n\u00famero de participantes y el per\u00edodo del estudio; describir las condiciones cl\u00ednicas de los participantes; y emplear intervenciones con medicamentos ya estudiados o aprobados para cualquier otra enfermedad en pacientes infectados con el nuevo coronavirus SARS-CoV-2 (2019-nCoV). Es esencial destacar que este art\u00edculo solo recoge los ensayos que figuran en la base de datos clinicaltrials. gov. Se identificaron 24 ensayos cl\u00ednicos relacionados con m\u00e1s de 20 medicamentos, como inmunoglobulina humana, interferones, cloroquina, hidroxicloroquina, arbidol, remdesivir, favipiravir, lopinavir, ritonavir, oseltamivir, metilprednisolona, bevacizumab y medicina tradicional china. Aunque el reposicionamiento de medicamentos tiene algunas limitaciones, el reposicionamiento de los ensayos cl\u00ednicos puede representar una estrategia atractiva porque facilita el descubrimiento de nuevas clases de medicamentos; estos tienen costos m\u00e1s bajos y tardan menos en llegar al mercado; y existen cadenas de suministro farmac\u00e9utico que apoyan la formulaci\u00f3n y la distribuci\u00f3n. clave Reposicionamiento de medicamentos; ensayos cl\u00ednicos como asunto; infecciones por coronavirus; virosis; neumon\u00eda viral; pandemias. Ensaios cl\u00ednicos de reposicionamento de medicamentos para o tratamento do COVID-19 RESUMO A Organiza\u00e7\u00e3o Mundial da Sa\u00fade (OMS) foi informada, em dezembro de 2019, sobre um surto de pneumonia por coronav\u00edrus em Wuhan, prov\u00edncia de Hubei (China). Posteriormente, em 12 de mar\u00e7o de 2020, 125 048 casos e 4 614 mortes haviam sido registrados. O coronav\u00edrus \u00e9 um v\u00edrus RNA envelopado do g\u00eanero Betacoronav\u00edrus, distribu\u00eddo em aves e em humanos e outros mam\u00edferos. A OMS designou a nova doen\u00e7a por coronav\u00edrus como COVID-19. Mais de 80 ensaios cl\u00ednicos foram iniciados para testar tratamentos para o coronav\u00edrus, incluindo alguns de reposicionamento de medicamentos para o COVID-19. Assim, em mar\u00e7o de 2020 realizou-se uma busca na base de dados clinicaltrials.gov. Os crit\u00e9rios de elegibilidade para os estudos recuperados foram: conter o n\u00famero identificador da base de dados clinicaltrials.gov; descrever o n\u00famero de participantes e o per\u00edodo do estudo; descrever as condi\u00e7\u00f5es cl\u00ednicas dos participantes; e utilizar interven\u00e7\u00f5es para tratamento de doentes infectados com o novo coronav\u00edrus SARS-CoV-2 (2019-nCoV) com medicamentos j\u00e1 estudados ou aprovados para qualquer outra doen\u00e7a. \u00c9 essencial salientar que este artigo apenas capturou ensaios listados na base de dados clinicaltrials.gov. Foram identificados 24 ensaios cl\u00ednicos envolvendo mais de 20 medicamentos, tais como imunoglobulina humana, interferons, cloroquina, hidroxicloroquina, arbidol, remdesivir, favipiravir, lopinavir, ritonavir, oseltamivir, metilprednisolona, bevacizumabe e medicamentos chineses tradicionais. Embora o reposicionamento de medicamentos tenha algumas limita\u00e7\u00f5es, os ensaios cl\u00ednicos de reposicionamento podem representar uma estrat\u00e9gia atraente, porque facilitam a descoberta de novas classes de medicamentos, t\u00eam custos mais baixos, levam menos tempo para chegar ao mercado e se beneficiam de cadeias de fornecimento farmac\u00eautico j\u00e1 existentes para formula\u00e7\u00e3o e distribui\u00e7\u00e3o. Palavras-chave Reposicionamento de medicamentos; ensaios cl\u00ednicos como assunto; infec\u00e7\u00f5es por coronavirus; viroses; pneumonia viral; pandemias.",
            "latex": null,
            "type": "table"
        }
    },
    "back_matter": []
}